Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Melanoma 8Head and Neck Neoplasms 8Lung Neoplasms 6Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Glioblastoma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable or Metastatic Solid Tumors 1Thymus Neoplasms 1Thymoma 1Spinocerebellar Degenerations 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × epacadostat × Clear all
NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡